Health · Medical Research · 1 hr ago
Verastem reports early results for experimental cancer drug
Verastem Oncology reported early results for its experimental drug, VS-7375, from a small study.
The study included people with metastatic pancreatic and colorectal cancers and advanced non-small cell lung cancer.
The drug targets KRAS G12D, a common cancer-driving mutation, and is designed to bind to two states of the mutation.
Tumor response rates ranged from 36% to 50% in pancreatic cancer, and were 33% in colorectal cancer and 43% in lung cancer.
The results give Verastem an early position in a crowded field, where Revolution Medicines has an approved drug for pancreatic cancer and is also developing a G12D treatment.
Larger trials are needed to show whether VS-7375 works, and Verastem says a Phase 3 pancreatic cancer trial will begin by the end of the year.
It expects to enroll the first patients in Phase 3 trials for colorectal and lung cancer in the first half of next year.
Verastem Oncology reported early results suggesting its experimental drug VS-7375 may help some patients with three types of cancer.
The Phase 1/2 study found response rates of 36% to 50% among patients with metastatic pancreatic cancer, 33% among colorectal cancer patients and 43% among patients with advanced non-small cell lung cancer.
VS-7375 targets the KRAS G12D mutation and is designed to bind to both its “on” and “off” states.
Verastem plans to begin three late-stage trials and said it has reached agreement with the FDA on a Phase 3 pancreatic cancer trial.
The findings are preliminary, and the drug must succeed in larger trials.
- Who
- Verastem Oncology, which is developing the experimental drug VS-7375.
- What
- The company reported early study results for the drug in three types of cancer.
- When
- Wednesday, October 14, 2026.
- Where
- Not stated.
- Why
- VS-7375 targets the KRAS G12D mutation, which drives cancer.
This story does not have two clearly opposing sides.
Revolution Medicines won FDA approval for Rasonque, according to BioPharma Dive.
Verastem released early data on VS-7375 and announced a $250 million stock offering.
Verastem said its Phase 3 pancreatic cancer trial would begin.
Verastem expects to enroll the first patients in colorectal and lung cancer Phase 3 trials.
- Drug
- VS-7375
- Target
- KRAS G12D mutation
- Pancreatic cancer response rates
- 36% to 50%
- Colorectal cancer response rate
- 33%
- Non-small cell lung cancer response rate
- 43%
- Stock offering
- $250 million
2 sources
What people are saying
a competitive profile
transformative day